Aemophilia C News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The phase 2 AZALEA-TIMI 71 trial in AF shows "an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban.

United statesDan bloomfieldMarc sabatineNational blood clot allianceDrug administrationAnthos therapeuticsThenew england journalNorth americaLatin americaMiddle eastLeslie lakeAtrial fibrillationF atrial fibrillationAnticoagulation therapyErebrovascular accidentVa cerebrovascular accident